The Bushell Chair of Neurology at the University of Sydney shared his insight into the latest data on CNM-Au8 as a potential treatment for amyotrophic lateral sclerosis and the frameshift in treatment that it represents. [WATCH TIME: 3 minutes]
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 1, 2022.
To build off the data, Cerevance plans on initiating additional phase 2/3 studies evaluating CVN424, including a trial assessing its potential as a standalone treatment.
This year’s meeting, themed “the Great Neuro-Reunion,” will feature a dual virtual and in-person format, spanning 9 days and including more than 200 sessions and 11 plenaries, as well as featuring 2400 abstracts presentations.
The virtual MJH Life Sciences Sleeves Up Blood Drive, put on by NeurologyLive®'s parent company, will be held from March 31 through April 30, 2022.
Annual progression rates to dementia were 14.7% for those with mild behavior impairment and 8.3% for the those without neuropsychiatric symptoms, with reversion rates of 2.5% and 5.3%, respectively, for each group.
The president and chief executive officer of The ALS Association provided insight on the most pressing needs for patients with ALS and the organization’s focus going forward. [WATCH TIME: 5 minutes]
In a sensitivity analysis that excluded women with evidence of possible demyelinating events before MS diagnosis, the associations between pregnancy-related ICD-10 code recording and disease risk were even more pronounced.
The company anticipates the first patient to be screened in May 2022, with a primary end point of cognitive decline at 18 months, measured by the Clinical Dementia Rating-Sum of Boxes.
FDA panelists expressed concern over the drug's efficacy and data analysis, indicating the need for a confirmatory clinical trial.
In preclinical studies, the investigational agent has demonstrated a clearance of both pyroglutamate modified and unmodified Aß plaque in brain tissue concentrations.
Mind Moments®, a podcast from NeurologyLive®, brings you exclusive interviews with Scott Demarest, MD, MSCS, and Kelly Knupp, MD, MSCS, FAES. [LISTEN TIME: 21 minutes]
The neurologist and assistant professor at the University of Toronto addressed the issues within Alzheimer drug development, the boom of biomarkers, and how retinal imaging can have a multilevel positive impact.
A study recently demonstrated that targeting longer-term intensive blood pressure control over a 4-year period may be associated with a subtle but significant increase in cerebral blood flow.
The investigators concluded that the MIDAS questionnaire may be a useful tool in the development, testing, and prescription of cost-effective medications for those with migraine whose direct and indirect costs are high.
Two experts at Jefferson Health discuss several topics related to advances in neurosurgery, technology, and the future of minimally invasive procedures.
The investigational antisense oligonucleotide, previously known as IONIS-C9Rx, failed to meet any of the secondary efficacy end points in its phase 1 trial but was well-tolerated. The companies plan to present the data at a future medical meeting.
The president and chief executive officer of The ALS Association provided insight on the availability of genetic testing for ALS and the organization’s efforts to increase access for the future. [WATCH TIME: 2 minutes]
Patient respondents documented a minimum acceptable treatment benefit of 39% if it meant it reduced their risk of long-term problems from 10% to 0%, and a lower chance of benefit to undergo noninvasive over invasive surgery.
Abnormal scores on cognitive testing persisted in 50% of patients without a pre-COVID history of cognitive abnormalities, irrespective of the presence or absence of a neurological complication during hospitalization.
The president and chief executive officer of The ALS Association highlighted a few of the major developments in the ALS field over the past decade, led by advances in technology. [WATCH TIME: 3 minutes]
The decision expands the indication of Fintepla, developed by Zogenix, beyond Dravet syndrome to pediatric patients age 2 years and older with the developmental and epileptic encephalopathy.
Here's what is coming soon to NeurologyLive®.
Jefferson Kinney, PhD, founding chair of the department of brain health at UNLV, discussed the ways a new NIH grant will assist in building a robust neuroscience research infrastructure at the Center for Neurodegeneration and Translational Neuroscience.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is headache and migraine.
How Tracy Dixon-Salazar, PhD, the executive director of the LGS Foundation, went from a new mother to a neuroscientist, and her decades-long quest to improve the lives of patients like her daughter, Savannah.
Neurology News Network for the week ending March 26, 2022. [WATCH TIME: 4 minutes]
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 25, 2022.